About Us

GCAC’s innovative Ethereum-powered platform, Citizen Green Efixii, is designed to solve one of the principal pain points for medical cultivators and consumers alike – the compliance, authentication, tracking, and certification of products to ensure quality, consistency, and most importantly, efficacy.

GCAC is a global leader in designing, developing, SaaS licensing, and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world’s first end-to-end – from patient to regulator – medical cannabis data solutions. We use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain, and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data.
Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from SaaS licensing its technology, and acquiring high-quality cannabis datasets that improve patient outcomes and become the world’s largest cannabis efficacy data provide.

For more Company information,
please visit

Citizen Green Efixii is the first platform of its kind for the medical cannabis industry. Its end-to-end solution – trademarked ‘Seed2Seed’ – is designed to enable medical professionals, cultivators, and regulator s to create better patient outcomes. The platform provides tools for every stage in the process to record best growing practices, certify compliance, enhance patient confidence, and improve the treatment experience. This is accomplished by leveraging multiple interlocking technologies, including mobile applications, artificial intelligence, smart databases, and an Ethereum blockchain.

Cannabis as a plant is highly variable by nature. To better understand the product, we verify eachgram’s lifecycle from cultivation to consumption via blockchain attestation. Thousands of resulting data sets provide clear evidence of “what happens to someone at a given point in time when a specific cannabis product is used to treat a specific symptom under a set of circumstances”. This data is processed by the company’s ‘Pain to Strain’ machine learning algorithm and can generate ‘averaged’ efficacy ratings on a per product-treatment basis. GCAC’s CitizenGreen Efixii technologies provide the medical cannabis data that cultivators need to create the best products, regulators need to write meaningful regulations, doctors need to write correct prescriptions, and patients need to confidently use products.

From Our Newsroom

GCAC and ABBEY TECHNOLOGIES CEO ROUNDTABLE DISCUSSES THE IMPACT OF CROSS-FI

GCAC To Launch Sales Initiative for Small & Medium Cultivators at Cannabis Business Europe 2021

GCAC ADDS MORE TOKENS TO BALANCE SHEET THROUGH CROSS-FI BUYBACK PROGRAM